PHRM 542 Oncology Supportive Care Myelosuppression

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/46

encourage image

There's no tags or description

Looks like no tags are added yet.

47 Terms

1
New cards

Define cytotoxic anticancer treatments

Treatments that target rapidly dividing cells

2
New cards

Define biologic anticancer treatments

Treatments that target intracellular signaling

3
New cards

Define immunotherapies as anticancer treatment

Treatments that modulate the immune system

4
New cards

Define a grade 1 adverse event

MILD

Asymptomatic or mild symptoms

Clinical or diagnostic observations only

Intervention not indicated

5
New cards

Define a grade 2 adverse event

MODERATE

Minimal, local or noninvasive intervention indicated

Limiting age appropriate instrumental ADL

6
New cards

Define a grade 3 adverse event

Severe or medically significant but not immediately life-threatening

Hospitalization or prolongation of hospitalization indicated

Disabling = limiting self care ADL

7
New cards

Define a grade 4 adverse event

Life-threatening consequences

Urgent intervention indicated

8
New cards

Define a grade 5 adverse event

Death related to AE

9
New cards

What is used to reduce the incidence of febrile neutropenia (FN)?

Myeloid growth factors (MGF's)

10
New cards

Define febrile neutropenia (FN)

Single temperature ≥ 38.3ºC orally or 38.0ºC over 1 h

AND

Neutropenia of < 500 cells/mm^3 or < 1000 cells/mm^3 and a predicted decline to ≤ 500 cells/mm^3 over the next 48 hours

11
New cards

What are used to manage chemotherapy-induced anemia?

Erythropoiesis-stimulating agents (ESAs)

12
New cards

What are risks associated with neutropenia?

Increased risk of infection

Inability of body to amount an immune response to pathogen

13
New cards

Describe the relationship between neutrophil count and mortality from uncontrolled infection

INVERSE RELATIONSHIP

Nadir neutrophil count > 1000/mm^3 = little risk of infection

Nadir neutrophil count < 500/mm^3 = risk of death is markedly increased

14
New cards

What is the normal half-life of a neutrophil cell?

6-12 hours

15
New cards

What are notable examples of medications used to treat neutropenia?

Filgrastim

Pegfilgrastim

16
New cards

What reduces the duration and severity of neutropenia?

The use of G-CSFs with antimicrobials

17
New cards

When is G-CSF primary prophylaxis given for neutropenia?

Given AUTOMATICALLY with cycle 1

18
New cards

When is G-CSF secondary prophylaxis given for neutropenia?

Given AFTER a patient started

19
New cards

Why might a patient be given secondary prophylaxis for neutropenia?

Patient experiences FN

Prolonged recovery of counts (prolonged neutropenic event)

If either of these, ADD filgrastim or pegfilgrastim

20
New cards

Define curative intent

The medical goal of curing a disease or condition

21
New cards

Define palliative intent

A medical care approach that focuses on relieving symptoms and improving the quality of life for patients with serious or life-threatening illnesses, rather than curing the disease itself

22
New cards

Define a high risk regimen for FN

Regimens where clinical trials show an incidence of FN ≥ 20%

23
New cards

Define an intermediate risk regimen for FN

Regimens which show an incidence of FN between 10-20%

24
New cards

When is FN prophylaxis automatically given?

If the patient is CURATIVE intent AND the regimen is HIGH risk

Give either filgrastim or pegfilgrastim

25
New cards

When should patient risk factors be assessed for FN primary prophylaxis?

If regimen has an intermediate risk for FN

26
New cards

When should G-CSF primary prophylaxis be considered for a patient on an intermediate risk regimen?

Prior chemotherapy or radiation therapy

Persistent neutropenia

Bone marrow involvement by tumor

Recent surgery and/or open wounds

Hepatic dysfunction (bilirubin > 2.0)

Renal dysfunction (CrCl < 50)

Age > 65 years receiving full chemotherapy dose intensity

27
New cards

Which medication is a short-acting G-CSF?

Filgrastim (and biosimilars)

28
New cards

What is the daily dose of filgrastim?

5 mcg/kg/daily SQ

Round to the nearest full vial size = 300 mcg or 480 mcg

29
New cards

When should filgrastim be started?

The next day or up to 3 days after completion of myelosuppressive chemotherapy and treat through post-nadir recovery

30
New cards

How long should filgrastim be continued?

Up to 14 days or until nadir has passed

31
New cards

When should filgrastim be discontinued?

If ANC > 10,000/mm^3 after expected chemotherapy-induced nadir occurs

32
New cards

What is the MOA of filgrastim?

Stimulates the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity

33
New cards

What medication is a long-acting G-CSF?

Pegfilgrastim (and biosimilars)

34
New cards

What is the dose of pegfilgrastim and when should it be administered?

6 mg SQ

Administered 1 day after myelosuppressive chemotherapy (up to 72 hours after is acceptable)

35
New cards

How many days should there be between the dose of pegfilgrastim and the next cycle of chemotherapy?

At least 12 days

36
New cards

What makes pegfilgrastim a long acting CSF?

Created by adding a polyethylene glycol molecule to G-CSF

37
New cards

What is the notable toxicity of myeloid growth factors?

Bone pain

38
New cards

What are baseline investigations for anemia in patients with cancer receiving chemotherapy?

Drug exposure history

Review of peripheral blood smear

Analysis of iron, TIBC, transferrin sat., ferritin, folate, B12

Assessment of reticulocyte found, occult blood loss and renal insufficiency

BASELINE ERYTHROPOIETIN LEVEL

39
New cards

What are treatment options for anemia as a result of chemotherapy?

Packed red blood cell transfusion

Erythropoiesis-stimulating agent (ESAs)

Iron replacement

40
New cards

When is a packed red blood cell transfusion given?

Progressive decline in hemoglobin due to chemotherapy (< 8)

Dyspnea, tachycardia, chest pain, syncope

41
New cards

What are examples of ESAs?

Epoetin alfa

Darbepoetin

42
New cards

What is the MOA of epoetin alfa?

Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells

Induces the release of reticulocytes from the bone marrow into the blood stream, where they mature to erythrocytes

43
New cards

What is the onset of epoetin alfa?

Within 10 days

44
New cards

What is a notable difference between epoetin alfa and darbepoetin?

Darbepoetin has an increased half-life compared to epoetin alfa

SQ half-life is longer than IV half-life for both drugs

45
New cards

What is the onset of darbepoetin?

Typically 2-6 weeks

46
New cards

What are risks associated with the use of ESA in cancer?

Increased thrombotic events

Possible decreased survival

47
New cards

What are the goals of the use of ESA in cancer?

Transfusion avoidance

Gradual improvement in anemia related symptoms